FDA

FDA Articles

Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.
ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss drug giant...
Privately held start-up Sprout Pharmaceuticals received FDA approval on Tuesday for its flibanserin pill with the trade name Addyi.
ThinkstockEsperion Therapeutics, Inc. (NASDAQ: ESPR) had a huge move in Monday’s trading session as the result of an analyst upgrade but it looks like this company has kept the rally alive into...
Bristol-Myers Squibb announced that the FDA has now extended the action date for the supplemental biologics license application for Opdivo in the war against advanced melanoma.
Aquinox Pharmaceuticals made waves in the market Friday morning, with shares up over 200%, after it announced results from a Phase 2 trial.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
ThinkstockThere are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of late, and it is a...
Sunesis Pharmaceuticals probably wishes that this Friday never happened, as shares were down almost 70% just after the opening bell.
XOMA Corp. (NASDAQ: XOMA) stumbled in trading Wednesday morning, perhaps fell off a cliff might be more accurate.
Dyax announced on Tuesday that the FDA has granted a key breakthrough therapy designation for the investigation of DX-2930 for hereditary angioedema .
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
Sarepta Therapeutics announces the completion of the rolling submission of a New Drug Application to the FDA for eteplirsen.
This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more than just one drug candidate.
24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background information has also been added on each, as well as how shares have been moving and the consensus price...